Last reviewed · How we verify
NCT04866056
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Phase 1, PHASE2 trial testing Jaktinib in Myelodysplastic Syndromes in 1 participant. Terminated before completion.
10 June 2022
Quick facts
| Lead sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 30 September 2021 |
| Primary completion | 10 June 2022 |
| Estimated completion | 10 June 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Jaktinib — full drug profile →
- azacitidine (azacitidine) — full drug profile →
Conditions studied
- Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
- Myeloproliferative Neoplasms — all drugs for Myeloproliferative Neoplasms →
- Myelofibrosis — all drugs for Myelofibrosis →
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd — full company profile →
Who can join
18 and older, any sex, with Myelodysplastic Syndromes or Myeloproliferative Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis. Giving Jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04866056
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Jaktinib
Trials testing the same drug.
- NCT06193148 — A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants · Phase 1 · completed
- NCT05255237 — Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata · Phase 3 · completed
- NCT05051761 — Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata · Phase 3 · completed
- NCT04612699 — A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis · Phase 2 · completed
- NCT04617028 — Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis · Phase 3 · completed
Other recruiting trials for Myelodysplastic Syndromes
Currently open trials in the same condition.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06303193 — Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or · Phase 1, PHASE2 · recruiting
- NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
- NCT07283900 — Ascorbate in Myelodysplastic Syndrome · Phase 2 · recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
Other Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials
Trials by the same sponsor.
- NCT05279001 — A Safety and Tolerability Study of Jaktinib · Phase 1 · unknown
- NCT06193148 — A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants · Phase 1 · completed
- NCT06132243 — Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions · Phase 1 · completed
- NCT05864573 — Study of ZGGS15 in Patients With Advanced Solid Tumors · Phase 1 · completed
- NCT05584800 — Study of ZGGS18 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04866056 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Last refreshed: 1 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04866056.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing